
Join Dr. Schmidt as he describes the pathophysiology of bullous pemphigoid, as well as novel research avenues to better understand this complicated disease.

Join Dr. Culton as she discusses the unmet treatment needs in bullous pemphigoid, and the importance of understanding pathophysiology in disease management.

Join Dr. Meijer as he highlights the signs and symptoms of bullous pemphigoid, and the importance of accurate and prompt diagnosis.

Join Dr. Murell as she shares novel treatments for bullous pemphigoid and how these may help fill current gaps in treatment options.

An interactive patient case tool involving a deeper dive into assessing clinical presentation when diagnosing bullous pemphigoid (BP)
Explore the mechanism of disease of bullous pemphigoid (BP), including the roles of autoimmunity and type 2 inflammation, in this informative video.
This static infographic covers the clinical presentations, diagnostic challenges, and disease burden of bullous pemphigoid (BP), a chronic relapsing autoimmune skin disease. Review the steps of diagnosis, which include clinical assessment and laboratory work. Explore comorbidities associated with BP and how they impact patient quality of life.
Join experts Dédée Murrell, Donna Aline Culton, Joost Meijer and Enno Schmidt for an educational presentation on the clinical presentation, disease burden, diagnosis, and underlying pathophysiology of bullous pemphigoid (BP). Dive deeper into unmet needs and treatment challenges faced by these patients and how targeted therapies may address them.
In this ADVENT symposium at the 2024 EADV meeting, Professor Enno Schmidt discusses the pathophysiology of BP, focusing on autoimmunity and the role of type 2 inflammation.
In this ADVENT symposium at the 2024 EADV meeting, Professor Joost Meijer highlights the heterogeneous nature of BP and the resultant burden for patients.
This symposium delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. It highlights both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies through a series of engaging panel discussions with Drs Eichenfield, Elmariah, Culton, and Hawkes.

Highlights from the ADVENT educational symposium at EADV 2024 discussing the current understanding of the science and treatment landscape in bullous pemphigoid (BP).